Dishman Carbogen Amcis Ltd

- No major new CAPEX programs planned currently; only maintenance CAPEX (about 4–5% of gross block) ongoing. - Debt increased in the last financial year due to expansion projects; no further significant increase in net debt is expected going forward. - The company prefers to use debt as a financial tool rather than equity because cost of debt is lower than equity. - There was a suggestion to deleverage and focus on paying down debt before incurring growth CAPEX, but the company intends to keep debt on books for leverage and strategic reasons. - No explicit mention of impending new fundraising through debt or equity in the near term. - Related party loan repayment is planned to clear before fiscal year-end, reducing related-party exposures and potentially impacting debt profile.

- Most major CAPEX projects outside India are completed, including the new French facility (~$50 million), Swiss ADC expansion, and Indian lab and infrastructure upgrades. - Future CAPEX will mainly be maintenance-related, around 4-5% of the gross block, estimated at CHF 35-40 million annually for FY '24 and FY '25. - A significant upcoming expense is the digital transformation project implementing SAP across Carbogen Amcis, aimed at streamlining operations and delivering cost benefits long-term. - The Hunzenschwil facility expansion project is currently on hold, with the land procured and preliminary engineering completed; no additional debt is planned to finance this at present. - Management views these investments as strategic, enabling long-term growth and enhanced manufacturing capabilities, particularly in formulations and injectable products. - No immediate major new CAPEX beyond maintenance and digital transformation; growth CAPEX to be reconsidered upon reaching revenue milestones (~Rs. 3,200-3,500 crore).

- The company anticipates a top-line growth of 12% to 15% CAGR over the next 5 years. - Management is confident of sustainable growth, having addressed past cyclical challenges, improving manufacturing quality, manpower, and processes. - The Bavla facility, despite EDQM inspection delays, is expected to perform strongly with revenues higher than the last financial year and no seasonality impact. - Investment in new capacities like the cells facility is already showing promising progress with revenue reaching 50% of the second-year target shortly after launch. - The company foresees double-digit growth in top line and over 20% growth in EBITDA, aiming to return to pre-2019 profitability levels. - Long-term growth confidence is based on the industry’s significant gap and contract research and manufacturing demand, expected to last at least two decades.

- The company anticipates top-line growth of 12% to 15% CAGR over the next 5 years (Page 11). - Targeting EBITDA margin improvement back to 25%-26% levels seen in 2019-2020 (Page 10). - Expecting at least 20% plus EBITDA growth in FY '24 compared to FY '23, supporting significant PAT improvement (Page 9). - Confident about consistent top-line and profitability growth, moving into positive profit territory in the current fiscal year (Page 9). - Growth attributed to resolving past challenges (e.g., EDQM inspection delays) and ramp-up of the Bavla facility alongside strong overseas subsidiary performance (Page 10). - Projected bright future over next two decades due to market gaps and strategic investments (Page 22).

- Carbogen Amcis has a very strong order book as of FY '23. - The company completed almost all one-off write-offs in FY '23. - They are confident of achieving at least double-digit top-line growth in FY '24. - EBITDA growth is expected to be aggressive, targeting 20%+ growth compared to FY '23. - This strong order book and growth outlook position the company on a significantly positive trajectory for profitability (PAT). - The management is positive about consistent growth and a strong pipeline supporting future orders, despite historical cyclicality and challenges.